文献速递心律失常

人群房颤筛查的成本效益:STROKESTOP研究

Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study.
PubMed 文献 · Eur Heart J · 2023-01-01

AIMS: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects.…

要点

  • 每1000名受邀筛查者中,筛查策略获得65个质量调整生命年且成本更低。
  • 筛查策略在99.2%的模拟中具有成本效益,在92.7%的模拟中节省成本。
  • 每1000人筛查减少10.6例卒中(95%CI:-22.5至1.4),但置信区间宽。

核心结论

  • 基于STROKESTOP研究,在老年人群中广泛开展房颤筛查具有成本效益。
  • 应努力提高筛查参与率。

主要发现

  • 每1000名受邀筛查者中,获得77个生命年和65个质量调整生命年。
  • 每1000人筛查减少10.6例卒中(95%CI:-22.5至1.4),其中缺血性卒中减少8.4例、出血性卒中减少2.2例。
  • 每1000人筛查增加1.0例系统性栓塞(95%CI:-1.9至4.1),减少2.9例出血相关住院(95%CI:-18.2至13.1)。

临床怎么用

  • 在老年人群中可考虑广泛开展房颤筛查,并采取措施提高筛查参与率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects. The STROKESTOP study, which randomised 27 975 persons aged 75/76 years into a screening invitation group and a control group, has a median follow-up time of 6.9 years. The aim of this study was to estimate the cost-effectiveness of population-based screening for AF using clinical outcomes. METHODS AND RESULTS: The analysis is based on a Markov cohort model. The prevalence of AF, the use of oral anticoagulation, clinical event data, and all-cause mortality were taken from the STROKESTOP study. The cost for clinical events, age-specific utilities, utility decrement due to stroke, and stroke death was taken from the literature. Uncertainty in the model was considered in a probabilistic sensitivity analysis. Per 1000 individuals invited to the screening, there were 77 gained life years and 65 gained quality-adjusted life years. The incremental cost was €1.77 million lower in the screening invitation group. Gained quality-adjusted life years to a lower cost means that the screening strategy was dominant. The result from 10 000 Monte Carlo simulations showed that the AF screening strategy was cost-effective in 99.2% and cost-saving in 92.7% of the simulations. In the base-case scenario, screening of 1000 individuals resulted in 10.6 [95% confidence interval (CI): -22.5 to 1.4] fewer strokes (8.4 ischaemic and 2.2 haemorrhagic strokes), 1.0 (95% CI: -1.9 to 4.1) more cases of systemic embolism, and 2.9 (95% CI: -18.2 to 13.1) fewer bleedings associated with hospitalization. CONCLUSION: Based on the STROKESTOP study, this analysis shows that a broad AF screening strategy in an elderly population is cost-effective. Efforts should be made to increase screening participation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lyth, Svennberg, Bernfort, et al. Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study. Eur Heart J. 2023. PMID: 36349968. doi:10.1093/eurheartj/ehac547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。